July 2026

communications@nrgoncology.org

www.nrgoncology.org

 

Welcome to the NRG Oncology eNewsletter

If you have a suggestion or would like to submit content to our Communications team, please email communications@nrgoncology.org

“Sarcoma awareness month is dedicated to raising the awareness of sarcoma that accounts for approximately 1% of all cancers. Sarcoma is not 1 disease but rather a collection of close to 100 different diseases each with its own natural history and biology. As we continued to work and support early detection, treatment, education, and research in this field, let us thank the patients, their families, friends and advocates who tirelessly work to bring awareness to this rare tumor.”


-Sarcoma Subcommittee Leadership: Dian Wang, MD, William Tseng, MD, and Scott Okuno, MD.


Want to learn more about sarcoma at NRG Oncology? Earlier this year we shared a NRG Oncology Podcast episode featuring various perspectives surrounding the topic of sarcoma. Our co-hosts interview NRG Sarcoma Subcommittee leaders Drs. Dian Wang and William Tseng on NRG’s specific aims and barriers with sarcoma research. Then, to shift the vantage point to the people sarcoma impacts, Major League Baseball player Chris Taylor and his wife Mary Taylor discuss what motivated them to start the CT3 Foundation and their ultimate goal in advancing sarcoma research. For the first time in NRG Oncology Podcast history, we were joined by our first ever guest co-host, Dr. Walter Curran. Listen at www.NRGOncology.org/Podcast



Protocol Support Committee (PSC) Column

The Impact of Navigation on Cancer Patients 

As patient advocates, we are tasked with navigating the complexities of healthcare systems. We stand between clinical and clerical spaces. We familiarize ourselves with every aspect of oncology care. Ultimately, we absorb burdens so that our patients don't have to. This article is for advocates, navigators, counselors - the glue.

 

When challenges seemingly outweigh the benefit, I am reminded of our impact on patients. I hope this helps you do the same.

 

Thank you,

 

Brittany McArn, OPN-CG, CPPN

Financial Navigation Manager

Outpatient Oncology Services

FirstHealth Cancer Center

Academy of Oncology Nurse and Patient Navigators


How Navigation Has Affected My Cancer Patients

December 2024 Vol 15, No 12: Journal of Oncology, Navigation & Survivorship

Written By: Brittany McArn, OPN-CG, CPPN, FirstHealth of the Carolinas, Inc. Oncology Services

 

Bright fluorescent lights, cold waiting room seats, no family, and a diagnosis of cancer....


Mr. Smith has just arrived for chemo teaching in preparation for his first infusion tomorrow. He’s been diagnosed with stage IV pancreatic cancer. At 78 years old, Mr. Smith finds himself alone and unsure how he will get through this. A widower with no children; his only brother passed away from cancer just a year ago. He wants to be strong, but reality overtakes his thoughts: “I have no one.” As he listens for his name, fear begins to set in.

NRG Study News & New Protocols in Development

New Protocols Under Development

NRG Oncology has issued a chart of new protocols under development. These protocols will include the study’s disease site, title, Principal Investigator, and any comments pertaining to the study’s anticipated activation.



The updated listing as of June 30, 2026 can be found here.

Comparing Two Common Treatments to Determine a Standard of Care for Patients with Locoregionally Advanced Head and Neck Cancer and a Contraindication to Cisplatin (NRG-HN016, The CONCISE Trial) 

Last month, NRG Oncology activated the NRG-HN016 trial, also known as the “CONCISE” trial, for patients with locoregionally advanced head and neck cancer with a contraindication to cisplatin. This pragmatic phase III randomized study will be comparing radiotherapy (RT) and carboplatin/paclitaxel to RT and cetuximab treatments to determine which regimen improves outcomes for these patients. 

NRG-GU015 “ARCHER” Study Webinar Recording

A webinar recording is now available for the NRG-GU015 trial, also known as the “ARCHER” study. The ARCHER study is testing shorter duration radiation therapy versus the usual radiation therapy in patients receiving the usual chemotherapy treatment for bladder cancer. Watch the webinar

Advocate Angle

Genetic Risk: A Patient’s Perspective on Testing



Written by Catherine DiMare-D’Souza, MS, IPAM, CMPPTM

Twenty years ago, hereditary breast and ovarian cancer (HBOC) wasn’t even mentioned during my routine women’s health appointments. It was only by chance that a nurse practitioner shared with me her family’s history of breast cancer and its link to a mutation in a gene called BRCA, which is now very familiar to most people. Because my paternal grandmother and her two sisters died from breast cancer at an early age, the conversation made me question whether there could be a hereditary element to breast cancer in my own family.

NRG Oncology Podcast

New Episode TODAY!

Today we aired a new episode to kick off the NRG Meeting in Denver! First, we speak with Dr. Jiayi Huang on the NRG-CC017 in honor of Glioblastoma Awareness Day. Second, we dive into the challenges faced by larger institutions with Dr. Jame Abraham – Part 2 of a series on challenges at smaller versus larger institutions. Follow us today so you can be alerted as new episodes go live! www.NRGOncology.org/Podcast

Member News

Dr. Allan Covens appointed member of the Order of Canada

Congratulations to Allan Covens, MD for his recent appointment as a member of the Order of Canada for his outstanding achievements as a globally recognized leader in gynecologic oncology. Dr. Covens is the Professor and past Chair of the division of Gynecologic Oncology at the University of Toronto, and Sunnybrook Health Sciences Centre. He is currently the Chair of the NRG Oncology GYN Rare Tumor Subcommittee and the NRG Oncology Canadian Members Subcommittee; a core member of the NRG Oncology Gynecologic Cancer Committee; and a member of the NRG Oncology Cervix/Vulva Cancer Subcommittee. Read more about the Order of Canada Appointees on The Governor General of Canada website.

Dr. William Small named president of American Radium Society

Our congratulations to William Small, Jr., MD for being named president of the American Radium Society, the nation’s oldest multidisciplinary cancer society devoted to the treatment of cancer. Dr. Small is Professor and Chairman of the Department of Radiation Oncology, Stritch School of Medicine, Loyola University Chicago, and Director of the Cardinal Bernardin Cancer Center. He is currently a Vice Chair of the NRG Oncology Publications Committee; was the past Vice Chair of the NRG Oncology Gynecological Cancer Committee and a former member of the NCI Gynecological Steering Committee. Read the press release from Dr. Small’s institution, Loyola Medicine.

Memorial

Dr. Maura Gillison



NRG Oncology and RTOG Foundation mourns the loss of Dr. Maura Gillison, a giant in the field of head and neck oncology. Dr. Gillison passed away on June 21, 2026 surrounded by her family. Read the message from NRG Oncology.

Other News

PBCC funded study shows GLP-1 use linked to lower breast cancer incidence – Update from ASCO 2026

Research supported by the Pennsylvania Breast Cancer Coalition (PBCC) was recently featured at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The study, led by 2023 PBCC research grant recipient Dr. Elizabeth McDonald of Penn Medicine, examined the potential impact of GLP-1 medications on breast cancer incidence. Working with fellow Penn Medicine researchers, including former PBCC Potamkin Prize winner Dr. Mitchell Schnall, Dr. McDonald analyzed imaging data from a large cohort of women to investigate whether GLP-1 use was associated with lower rates of breast cancer diagnosis. Learn more about the study. The study also is making national media headlines with a recent feature story on Good Morning America (click here to watch).

 

Findings from NRG Oncology/NSABP B-35 on surgical management of DCIS

An analysis from the NRG Oncology/NSABP B-35 clinical trial found that postmenopausal women with hormone receptor-positive DCIS who received lumpectomy, whole-breast radiation, and endocrine therapy experienced only small differences in local recurrence based on surgical margin width. The findings, published in JAMA Surgery, analyzed data from the B-35 trial and suggest that many postmenopausal women with hormone receptor-positive DCIS may be able to safely avoid additional breast surgery when lumpectomy margins are close, offering the potential to reduce unnecessary surgeries while maintaining excellent outcomes. Read more


ACR Commission on Radiation Oncology Education Committee

The ACR Commission on Radiation Oncology Education Committee is looking for new members and accepts members at any level of their career (including trainees (residents/fellows) and attending physicians. The ACR Commission on Radiation Oncology Education Committee consists of radiation oncologists, physicists, and radiation biologists. and works in conjunction with the Council of Affiliated Regional Radiation Oncology Societies (CARROS). Click here for more information on responsibilities, academic opportunities, and how to apply.

 

REGISTER TODAY: Biology-guided Radiotherapy Webinar

Join us on July 23, 2026, 5-6 PM ET, 2-3 PM PT for the next webinar in the American College of Radiology (ACR) Radiation Oncology Webinar Series. Presenters include Dr. Henry Park at the Yale University, Dr. Joshua Schiff at the University of Southern California, and Dr. Tyler Watkins at City of Hope. This activity has been approved for AMA PRA Category 1 Credit. Register here

FOLLOW US

Facebook  Instagram  LinkedIn  X  YouTube  Bluesky